Please assess the completion status of the following clinical trial:

Trial Title: AflacLL1901 (CHOA-AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients must be less than 21 years of age at the time of study enrollment~* Diagnosis: Patients must be newly diagnosed with AML~* Patients with previously untreated primary AML who meet the customary criteria for AML with ≥ 20% bone marrow blasts as set out in the 2016 WHO Myeloid Neoplasm Classification are eligible.~* Attempts to obtain bone marrow either by aspirate or biopsy must be made unless clinically prohibitive. In cases where it is clinically prohibitive, peripheral blood with an excess of 20% blasts and in which adequate flow cytometric and cytogenetics/FISH testing is feasible can be substituted for the marrow exam at diagnosis.~* Patients with \<20% bone marrow blasts are eligible if they have:~  * A karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities,~ * the unequivocal presence of megakaryoblasts, or~ * Biopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including leukemia cutis)~* Performance Level: Patients with acceptable organ function and any performance status are eligible for enrollment~Exclusion Criteria:~* Patients with any of the following constitutional conditions are not eligible:~  * Fanconi anemia~ * Shwachman syndrome~ * Any other known bone marrow failure syndrome~ * Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Note: Enrollment may occur, pending results of clinically indicated studies to exclude these conditions.~* Other Excluded Conditions:~  * Any concurrent malignancy~ * Juvenile myelomonocytic leukemia (JMML)~ * Philadelphia chromosome positive AML~ * Biphenotypic or bilineal acute leukemia~ * Acute promyelocytic leukemia (APL)~ * Acute myeloid leukemia arising from myelodysplasia~ * Therapy-related myeloid neoplasms

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Aflac-AML Regimen for Low Risk AML Patients (Type: EXPERIMENTAL): Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:~* Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.~* Induction II - MA~* Intensification I - AE~* Intensification II - HD ARAC/LASP~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol.
- Aflac-AML Regimen for High Risk AML Patients (Type: EXPERIMENTAL): Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:~* Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.~* Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib~* Induction II - MA~* Induction II for FLT3-ITD patients - MA with Sorafenib~* Intensification I - AE~* Intensification I for FLT3-ITD patients - AE with sorafenib~* Intensification II - HD ARAC/LASP~* Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib~* Hematopoietic stem cell transplantation (HSCT)~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues